NCT05900895View on ClinicalTrials.gov

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Olaparib

Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.

DRUG

17b-estradiol

17b-estradiol will be taken orally three times per day.

Trial Locations (1)

03756

RECRUITING

Dartmouth Cancer Center, Lebanon

All Listed Sponsors
collaborator

Dartmouth-Hitchcock Medical Center

OTHER

lead

Mary D Chamberlin

OTHER